Literature DB >> 24424189

Diagnosis and classification of Crohn's disease.

Martin W Laass1, Dirk Roggenbuck2, Karsten Conrad3.   

Abstract

Crohn's disease (CrD) is a chronic relapsing inflammatory bowel disease (IBD) potentially affecting any portion of the gastrointestinal tract from the mouth to the anus. CrD usually manifests between 15 and 30 years of age and presents typically with abdominal pain, fever, bloody or non-bloody diarrhoea, and weight loss. Paediatric patients may show failure to thrive, growth impairment, and delayed puberty additionally. Extraintestinal manifestations like arthritis, uveitis, and erythema nodosum are diagnosed in almost half of the patients. CrD is characterized by a discontinuous and ulcerous transmural inflammation often involving the ileocaecal region and leading to a stricturing or even fistulising phenotype in up to 50% of patients finally. Incidence and prevalence of CrD have been rising worldwide over the past decades. Although many details of the pathophysiology of CrD have been elucidated, no common aetiopathogenic model exists for all forms of CrD, presenting more an umbrella term for a phenotypically and genotypically heterogeneous clinical condition. In CrD, we see an inappropriate response of the innate and/or adaptive immune system to the intestinal microbiota in genetically predisposed individuals. The diagnosis of CrD is based mainly on patient's history and clinical examination and supported by serologic, radiologic, endoscopic, and histologic findings. Antibodies to Saccharomyces cerevisiae and autoantigenic targets such as glycoprotein 2 may aid in differentiating CrD from UC. Their single use, however, is limited by low sensitivity requiring antibody profiling for an appropriate serologic diagnosis. This review focuses on diagnostic and classification criteria of CrD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoantibody; Crohn's disease; Diagnostic criteria; Inflammatory bowel diseases; Ulcerative colitis

Mesh:

Substances:

Year:  2014        PMID: 24424189     DOI: 10.1016/j.autrev.2014.01.029

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  44 in total

Review 1.  Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature.

Authors:  Alice Sy; Nader Khalidi; Natasha Dehghan; Lillian Barra; Simon Carette; David Cuthbertson; Gary S Hoffman; Curry L Koening; Carol A Langford; Carol McAlear; Larry Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Antoine Sreih; Steven R Ytterberg; Gert Van Assche; Peter A Merkel; Christian Pagnoux
Journal:  Semin Arthritis Rheum       Date:  2015-07-26       Impact factor: 5.532

2.  Ischemic colitis caused by polycythemia vera: A case report and literature review.

Authors:  Shasha Zhang; Ruixue Lai; Xueqing Gao; Yufei Zhao; Yue Zhao; Jianhua Wu; Zhanjun Guo
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

3.  Serum protein profiling of adults and children with Crohn disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; Aggeliki Papadopoulou; Athanassios K Anagnostopoulos; George Karamanolis; George E Theodoropoulos; Amosy M'Koma; George T Tsangaris
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

4.  Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis.

Authors:  Chloe J Mitchell; Gordon S Howarth; Lauren C Chartier; Debbie Trinder; Ian C Lawrance; Li San Huang; Suzanne Mashtoub
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-09

5.  Disease progression-associated alterations in fecal metabolites in SAMP1/YitFc mice, a Crohn's disease model.

Authors:  Yosuke Komatsu; Yu Shimizu; Megumi Yamano; Mani Kikuchi; Kiminori Nakamura; Tokiyoshi Ayabe; Tomoyasu Aizawa
Journal:  Metabolomics       Date:  2020-04-10       Impact factor: 4.290

6.  Examining Psychosocial Mechanisms of Pain-Related Disability in Inflammatory Bowel Disease.

Authors:  Katherine M Fretz; Dean A Tripp; Laura Katz; Mark Ropeleski; Michael J Beyak
Journal:  J Clin Psychol Med Settings       Date:  2020-03

7.  Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.

Authors:  Shulan Zhang; Jing Luo; Ziyan Wu; Dirk Roggenbuck; Peter Schierack; Dirk Reinhold; Ji Li; Xiaofeng Zeng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Clin Transl Gastroenterol       Date:  2018-02-15       Impact factor: 4.488

8.  Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis.

Authors:  Alan Barnicle; Cathal Seoighe; John M Greally; Aaron Golden; Laurence J Egan
Journal:  Epigenetics       Date:  2017-05-30       Impact factor: 4.528

9.  Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.

Authors:  Pinelopi Nterma; Eleni Panopoulou; Eleni Papadaki-Petrou; Martha Assimakopoulou
Journal:  Pathol Oncol Res       Date:  2019-01-02       Impact factor: 3.201

Review 10.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.